Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Borderline Resectable Pancreatic Carcinoma”

141 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 141 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT05562297
What this trial is testing

Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic Cancer

Who this might be right for
Pancreatic Cancer, Stage IBPancreatic Cancer, Stage IIAPancreatic Cancer, Stage IIB+1 more
Shanghai Zhongshan Hospital 50
Not applicableLooking for participantsNCT05298722
What this trial is testing

Prediction of Surgical Resectability After FOLFIRINOX Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: the Role of Diffusion Weighted Magnetic Resonance Imaging, Radiomics and Liquid Biopsy (PeRFormanCe Trial)

Who this might be right for
Pancreatic Cancer
University Hospital, Ghent 45
Testing effectiveness (Phase 2)Ended earlyNCT01897454
What this trial is testing

Gemcitabine Hydrochloride, and Radiation Therapy in Patients With Borderline Resectable Pancreatic Cancer

Who this might be right for
Pancreatic AdenocarcinomaStage IIA Pancreatic CancerStage IIB Pancreatic Cancer+1 more
Albert Einstein College of Medicine 23
Testing effectiveness (Phase 2)Ended earlyNCT01431794
What this trial is testing

Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma

Who this might be right for
Pancreatic Ductal Adenocarcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 23
Not applicableStudy completedNCT02777463
What this trial is testing

The Prediction Using Diffusion MRI of the Response Evaluation in BRPC in NAT.

Who this might be right for
Pancreatic Cancer
Wakayama Medical University 28
Very early researchStudy completedNCT03153410
What this trial is testing

Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas

Who this might be right for
Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 11
Testing effectiveness (Phase 2)Active Not RecruitingNCT05908747
What this trial is testing

Efficacy and Safety of Surufatinib Combined With Gemcitabine and Albumin-bound Paclitaxel in the Peri-operative Treatment of Pancreatic Cancer

Who this might be right for
Pancreatic Cancer
Tianjin Medical University Cancer Institute and Hospital 29
Testing effectiveness (Phase 2)UnknownNCT02717091
What this trial is testing

Neoadjuvant FOLFIRINOX or Nab-paclitaxel With Gemcitabine for Borderline Resectable Pancreatic Cancer

Who this might be right for
Borderline Resectable Pancreatic Cancer
Nagoya University 50
Testing effectiveness (Phase 2)UnknownNCT01676259
What this trial is testing

SiG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer

Who this might be right for
Pancreatic Ductal AdenocarcinomaPancreatic Cancer
Silenseed Ltd 80
Large-scale testing (Phase 3)Study completedNCT01458717
What this trial is testing

Neoadjuvant Chemoradiation in Patients With Borderline Resectable Pancreatic Cancer

Who this might be right for
Pancreatic Cancer
Seoul National University Hospital 58
Not applicableUnknownNCT02781012
What this trial is testing

Project Survival-Prospective Biomarker Discovery

Who this might be right for
Pancreatic NeoplasmsPancreatic CancerPancreatitis+2 more
Pancreatic Cancer Research Team 436
Testing effectiveness (Phase 2)Ended earlyNCT01359007
What this trial is testing

FOLFIRINOX in Patients With Inoperable Pancreatic Cancer

Who this might be right for
Adenocarcinoma of Pancreas
University of Oklahoma 5
Testing effectiveness (Phase 2)Study completedNCT01661088
What this trial is testing

Neoadjuvant FOLFIRINOX and FDR-Gemcitabine With Concurrent IMRT in Patients

Who this might be right for
Pancreatic Cancer
University of Michigan Rogel Cancer Center 25
Not applicableStudy completedNCT05888129
What this trial is testing

Clinical Outcomes of Surgery After Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer

Who this might be right for
Postoperative Complications
Asan Medical Center 1
Testing effectiveness (Phase 2)UnknownNCT02305186
What this trial is testing

Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer

Who this might be right for
Pancreatic Cancer
Craig L Slingluff, Jr 68
Early research (Phase 1)Study completedNCT02308722
What this trial is testing

SBRT Pre-operatively for Pancreatic Cancer

Who this might be right for
Pancreatic Neoplasms
University of Oxford 12
Early research (Phase 1)Looking for participantsNCT06141031
What this trial is testing

Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma

Who this might be right for
Pancreatic Cancer
Washington University School of Medicine 18
Testing effectiveness (Phase 2)UnknownNCT03850769
What this trial is testing

Neoadjuvant Nab-Paclitaxel and S-1 in Borderline Resectable Pancreatic Cancer

Who this might be right for
Borderline Resectable Pancreatic Cancer
Peking Union Medical College Hospital 60
Testing effectiveness (Phase 2)Study completedNCT05262855
What this trial is testing

Study of [68Ga]FAPI-46 PET in Patients With Pancreatic Ductal Carcinoma

Who this might be right for
PDAC - Pancreatic Ductal AdenocarcinomaFAP
SOFIE 63
Not applicableStudy completedNCT02318095
What this trial is testing

Gemcitabine/Nab-Paclitaxel With HIGRT in Resectable Pancreatic Cancer

Who this might be right for
Resectable Pancreatic Cancers
Duke University 40
Load More Results